Increased unsaturated transcobalamin II in active autoimmune disease

Area of Science:

• Immunology
• Clinical Biochemistry
• Rheumatology

Background:

• Autoimmune diseases involve immune system dysregulation.
• Monitoring disease activity is crucial for effective patient management.
• Biomarkers like C3 and antinuclear antibodies are used, but their correlation with disease activity can vary.

Purpose of the Study:

• To investigate the relationship between transcobalamin II (T.C. II) concentrations and the activity of autoimmune diseases.
• To compare the utility of T.C. II levels as a disease activity marker against established markers.

Main Methods:

• Measurement of T.C. II concentrations in patient cohorts.
• Inclusion of patients with lupus erythematosus, dermatomyositis, autoimmune haemolytic anaemia, and immunosuppressed renal-transplant recipients.
• Correlation analysis of T.C. II levels with clinical disease course and other immunological markers (C3, antinuclear antibody, DNA-binding capacity).

Main Results:

• Transcobalamin II (T.C. II) levels were elevated during active phases of autoimmune conditions.
• Changes in T.C. II concentrations demonstrated a stronger correlation with the clinical course of autoimmune disease compared to C3, antinuclear antibody titre, or native DNA-binding capacity.

Conclusions:

• Transcobalamin II (T.C. II) shows potential as a sensitive biomarker for monitoring autoimmune disease activity.
• T.C. II levels may offer a more reliable indicator of disease progression than currently used immunological markers.